Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Fujian Akeylink Biotechnology Co., Ltd.

Fujian Cosunter Pharmaceutical Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Go., Ltd.

Jumbo Drug Bank Co., Ltd.

Xiongbin Xu

Shuhui Chen

Jian Li

Yong Wang

Charles Z Ding

Lihong Hu

Xiquan Zhang

Guoping Hu

Kevin X Chen

Kun Peng Wang

Jian Xiong

Xin Tian

Aiming Zhang

Cheng Xie

Yi Chen

Chun Sing Li

Lingyun Wu

Zhen Gong

Wen Jiang

Cailin Wang

Xiawei Wei

Ting Yao

Lun Lu

Xu You

Ning Jiang

Kun Wang

Ru Feng

Zhulian Jiang

Yaling Zhou

Jinping Li

Yong Cang

Zhigang Chi

Xuejin Zhang

Gang Li

Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.

Compound as porcupine inhibitor and use thereof

Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor. 

Uracil compound as c-MET/AXL inhibitor

A borate compound of an azetidine derivative, relating in particular to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof or a geometric isomer thereof, as well as a use thereof in the preparation of a drug used for the treatment or prevention of multiple myeloma. 

Borate of azetidine derivative

Disclosed are a crystal form of a c-MET inhibitor and a salt form thereof and a preparation method therefor. Specifically involved are the compound as shown in formula (I), and a salt form and a crystal form thereof, and also included is the use of the crystal form and the salt form in the preparation of medicines for treating cancers. 

Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor

Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma. 

Azetidine derivative

Disclosed in the present invention is a type of pyridone compounds as c-met inhibitors, and specifically disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof. 

Pyridone compound as c-met inhibitor

The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.

Linkers and their application towards ADC

Growing community of inventors

Shanghai, China

Xiongbin Xu